

Begoa Martn-Castillo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1602447/begona-martin-castillo-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

3,806
citations

38
h-index

61
g-index

80
ext. papers

4,189
ext. citations

4.7
avg, IF

5.07
L-index

#	Paper	IF	Citations
78	Metformin and Breast Cancer: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	4
77	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	25
76	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	3
75	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. <i>Aging</i> , 2020 , 12, 8-34	5.6	49
74	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. <i>Aging</i> , 2020 , 12, 4794-4814	5.6	21
73	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. <i>Aging</i> , 2020 , 12, 21057-21075.	5.6	1
72	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. <i>Frontiers in Oncology</i> , 2020 , 10, 620641	5.3	1
71	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. <i>Onc Immunology</i> , 2019 , 8, e1633235	7.2	39
70	The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. <i>Frontiers in Oncology</i> , 2019 , 9, 193	5.3	10
69	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. <i>Aging</i> , 2019 , 11, 2874-2888	5.6	18
68	clinical trials for anti-aging therapies. <i>Aging</i> , 2019 , 11, 6591-6601	5.6	2
67	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
66	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. <i>Carcinogenesis</i> , 2019 , 40, 27-40	4.6	9
65	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. <i>Carcinogenesis</i> , 2018 , 39, 601-613	4.6	35
64	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. <i>Aging Cell</i> , 2018 , 17, e12772	9.9	43
63	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. <i>Oncotarget</i> , 2018 , 9, 35687-35704	3.3	34
62	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. <i>Frontiers in Endocrinology</i> , 2018 , 9, 657	5.7	64

61	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. <i>Cell Cycle</i> , 2017 , 16, 1022-1028.	4.7	17
60	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. <i>Oncotarget</i> , 2017 , 8, 99223-99236	3.3	8
59	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. <i>Oncology Reports</i> , 2017 , 38, 263-270	3.5	7
58	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. <i>Histology and Histopathology</i> , 2017 , 32, 687-698	1.4	27
57	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017 , 8, 35019-35032	3.3	10
56	Metformin and cancer: Quo vadis et cui bono?. <i>Oncotarget</i> , 2016 , 7, 54096-54101	3.3	13
55	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 82185-82199	3.3	11
54	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. <i>Cell Cycle</i> , 2015 , 14, 3527-32	4.7	22
53	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. <i>Oncotarget</i> , 2015 , 6, 32317-38	3.3	26
52	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. <i>Oncotarget</i> , 2015 , 6, 7104-22	3.3	12
51	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. <i>Oncotarget</i> , 2015 , 6, 12279-96	3.3	41
50	An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients. <i>Scientific Reports</i> , 2014 , 4, 5743	4.9	2
49	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. <i>Cell Cycle</i> , 2014 , 13, 1132-44	4.7	54
48	Discovery and validation of an INflammatory PROtein-driven GAstic cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. <i>Oncotarget</i> , 2014 , 5, 1942-54	3.3	13
47	Oncobiguanides: Paracelsus' Law and nonconventional routes for administering diabetobiguanides for cancer treatment. <i>Oncotarget</i> , 2014 , 5, 2344-8	3.3	35
46	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. <i>Food and Chemical Toxicology</i> , 2013 , 60, 360-8	4.7	44
45	The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. <i>Cell Cycle</i> , 2013 , 12, 1166-79	4.7	126
44	The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. <i>Scientific Reports</i> , 2013 , 3, 2469	4.9	81

43	Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). <i>Cell Cycle</i> , 2013 , 12, 225-45	4-7	42
42	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. <i>Scientific Reports</i> , 2013 , 3, 2560	4-9	63
41	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. <i>Cell Cycle</i> , 2013 , 12, 555-78	4-7	113
40	Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. <i>Cell Cycle</i> , 2013 , 12, 3390-404	4-7	57
39	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. <i>Scientific Reports</i> , 2013 , 3, 2459	4-9	56
38	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. <i>Oncotarget</i> , 2013 , 4, 1484-95	3-3	29
37	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. <i>Investigational New Drugs</i> , 2012 , 30, 846-52	4-3	10
36	Metformin is synthetically lethal with glucose withdrawal in cancer cells. <i>Cell Cycle</i> , 2012 , 11, 2782-92	4-7	101
35	Metformin limits the tumorigenicity of iPS cells without affecting their pluripotency. <i>Scientific Reports</i> , 2012 , 2, 964	4-9	51
34	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. <i>Cell Cycle</i> , 2012 , 11, 865-70	4-7	31
33	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. <i>Cell Cycle</i> , 2012 , 11, 974-89	4-7	87
32	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. <i>Aging</i> , 2012 , 4, 480-98	5-6	93
31	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. <i>Oncotarget</i> , 2012 , 3, 1600-14	3-3	60
30	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). <i>Cell Cycle</i> , 2012 , 11, 4020-32	4-7	104
29	Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. <i>Cell Cycle</i> , 2012 , 11, 1235-46	4-7	50
28	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. <i>Oncology Reports</i> , 2012 , 27, 1887-92 ³⁻⁵		3
27	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. <i>Oncotarget</i> , 2012 , 3, 395-8	3-3	120
26	Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. <i>Drug Resistance Updates</i> , 2011 , 14, 212-23	23-2	51

25	Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 407, 412-9	3.4	40
24	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib. <i>Breast Cancer Research</i> , 2011 , 13, 401	8.3	3
23	Metformin: multi-faceted protection against cancer. <i>Oncotarget</i> , 2011 , 2, 896-917	3.3	238
22	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbixim) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. <i>International Journal of Cancer</i> , 2011 , 129, 1457-70	4.4	10
21	The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 355-64	4.4	139
20	Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 241-5	4.4	5
19	Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma. <i>Journal of Surgical Oncology</i> , 2011 , 104, 106-9	2.8	5
18	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. <i>Journal of Cellular Physiology</i> , 2011 , 226, 52-7	7	24
17	Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbixim) efficacy in KRAS wild-type tumor cells. <i>Journal of Cellular Biochemistry</i> , 2011 , 112, 10-29	4.7	34
16	Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. <i>Cell Cycle</i> , 2011 , 10, 3871-85	4.7	150
15	Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. <i>Cell Cycle</i> , 2011 , 10, 1499-501	4.7	68
14	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGF β -induced oncomiR miRNA-181a. <i>Cell Cycle</i> , 2011 , 10, 1144-51	4.7	97
13	Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 284-90	5	8
12	Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. <i>Aging</i> , 2011 , 3, 1063-77	5.6	59
11	The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. <i>Oncology Reports</i> , 2011 , 25, 135-40	3.5	33
10	Metformin against TGF β -induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. <i>Cell Cycle</i> , 2010 , 9, 4461-8	4.7	183
9	Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. <i>Cell Cycle</i> , 2010 , 9, 1057-64	4.7	181
8	Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 27-33	3.4	54

7	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. <i>Cell Cycle</i> , 2010 , 9, 3831-3838	4.7	147
6	Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). <i>International Journal of Oncology</i> , 2010 , 37, 669-78	4.4	40
5	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. <i>Cell Cycle</i> , 2010 , 9, 3807-14	4.7	103
4	If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, e207-9; author reply e210	2.2	28
3	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). <i>Clinical and Translational Oncology</i> , 2009 , 11, 455-9	3.6	51
2	Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. <i>International Journal of Oncology</i> , 2009 , 35, 1369-76	4.4	17
1	BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. <i>Molecular Carcinogenesis</i> , 2008 , 47, 157-63	5	51